{"id":"https://openalex.org/W1968156583","doi":"https://doi.org/10.1111/j.1463-1326.2009.01034.x","title":"Antidiabetic effects of 11\u03b2\u2010HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis","display_name":"Antidiabetic effects of 11\u03b2\u2010HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis","alternate_titles":[],"publication_year":2009,"publication_date":"2009-05-27","ids":{"openalex":"https://openalex.org/W1968156583","doi":"https://doi.org/10.1111/j.1463-1326.2009.01034.x","mag":"1968156583","pmid":"https://pubmed.ncbi.nlm.nih.gov/19527482"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2009.01034.x","doi":"https://doi.org/10.1111/j.1463-1326.2009.01034.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2009.01034.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1968156583"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076454979","display_name":"David J. Lloyd","orcid":"https://orcid.org/0000-0001-5924-0672","observed_orcids":["https://orcid.org/0000-0001-5924-0672"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"D. J. Lloyd","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA 91320, USA. dlloyd@amgen.com","Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA 91320, USA. dlloyd@amgen.com","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006335673","display_name":"Joan Helmering","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Helmering","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066972897","display_name":"David H. Cordover","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Cordover","raw_affiliation_strings":["Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066693196","display_name":"M. Bowsman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Bowsman","raw_affiliation_strings":["Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081992002","display_name":"Mingxin Chen","orcid":"https://orcid.org/0009-0006-5093-5420","observed_orcids":["https://orcid.org/0009-0006-5093-5420"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Chen","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042070146","display_name":"Clarence Hale","orcid":"https://orcid.org/0000-0001-9670-3330","observed_orcids":["https://orcid.org/0000-0001-9670-3330"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Hale","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063874764","display_name":"Preston Fordstrom","orcid":"https://orcid.org/0000-0002-4562-7128","observed_orcids":["https://orcid.org/0000-0002-4562-7128"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Fordstrom","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081161777","display_name":"Mingyue Zhou","orcid":"https://orcid.org/0000-0001-8022-2743","observed_orcids":["https://orcid.org/0000-0001-8022-2743"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Zhou","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039046689","display_name":"M. Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Wang","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. A. Kaufman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. A. Kaufman","raw_affiliation_strings":["Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Amgen, Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012830823","display_name":"Murielle M. V\u00e9niant","orcid":"https://orcid.org/0000-0002-1881-8252","observed_orcids":["https://orcid.org/0000-0002-1881-8252"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. M. V\u00e9niant","raw_affiliation_strings":["Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5076454979"],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":4.3306,"has_fulltext":false,"cited_by_count":43,"citation_normalized_percentile":{"value":0.94684906,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"11","issue":"7","first_page":"688","last_page":"699"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.37720000743865967,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.37720000743865967,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.26460000872612,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":0.23250000178813934,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/11beta-hydroxysteroid-dehydrogenase-type-1","display_name":"11\u03b2-hydroxysteroid dehydrogenase type 1","score":0.9129999876022339},{"id":"https://openalex.org/keywords/11beta-hsd1-inhibition","display_name":"11\u03b2-HSD1 inhibition","score":0.902999997138977},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.8730000257492065},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.6380000114440918},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.8510000109672546},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.9079999923706055},{"id":"https://openalex.org/keywords/glucose-homeostasis","display_name":"glucose homeostasis","score":0.9079999923706055},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.6439999938011169},{"id":"https://openalex.org/keywords/ldlr-knockout-mice","display_name":"Ldlr knockout mice","score":0.6320000290870667},{"id":"https://openalex.org/keywords/adipose-tissue","display_name":"adipose tissue","score":0.8080000281333923},{"id":"https://openalex.org/keywords/glucocorticoids","display_name":"glucocorticoids","score":0.8259999752044678},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.6299999952316284},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.6380000114440918},{"id":"https://openalex.org/keywords/antidiabetic-effect","display_name":"antidiabetic effect","score":0.550000011920929}],"concepts":[{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.7739682197570801},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6882431507110596},{"id":"https://openalex.org/C171089720","wikidata":"https://www.wikidata.org/wiki/Q193583","display_name":"Adipose tissue","level":2,"score":0.6736606359481812},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.670841634273529},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.6266807913780212},{"id":"https://openalex.org/C3018667095","wikidata":"https://www.wikidata.org/wiki/Q3455903","display_name":"Glucose homeostasis","level":4,"score":0.5990051031112671},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.5132379531860352},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.508445143699646},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4870195984840393},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.4869168996810913},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.43379876017570496},{"id":"https://openalex.org/C63645605","wikidata":"https://www.wikidata.org/wiki/Q103191","display_name":"Homeostasis","level":2,"score":0.431990385055542},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.42228639125823975}],"mesh":[{"descriptor_ui":"D000077154","descriptor_name":"Rosiglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000273","descriptor_name":"Adipose Tissue","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D001823","descriptor_name":"Body Composition","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002784","descriptor_name":"Cholesterol","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018345","descriptor_name":"Mice, Knockout","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019821","descriptor_name":"Simvastatin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D043205","descriptor_name":"11-beta-Hydroxysteroid Dehydrogenase Type 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2009.01034.x","doi":"https://doi.org/10.1111/j.1463-1326.2009.01034.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2009.01034.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:19527482","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19527482","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W166246128","https://openalex.org/W1745264954","https://openalex.org/W1951484275","https://openalex.org/W1967553740","https://openalex.org/W1975045088","https://openalex.org/W1976973182","https://openalex.org/W1979562529","https://openalex.org/W1980629926","https://openalex.org/W1986062625","https://openalex.org/W1994641000","https://openalex.org/W1995290986","https://openalex.org/W1996611951","https://openalex.org/W2000779764","https://openalex.org/W2019728240","https://openalex.org/W2021943148","https://openalex.org/W2034105444","https://openalex.org/W2040031363","https://openalex.org/W2060449981","https://openalex.org/W2071151531","https://openalex.org/W2077428021","https://openalex.org/W2084415944","https://openalex.org/W2086583788","https://openalex.org/W2088329000","https://openalex.org/W2092020543","https://openalex.org/W2096253518","https://openalex.org/W2100159933","https://openalex.org/W2113587271","https://openalex.org/W2117268230","https://openalex.org/W2120768282","https://openalex.org/W2127125241","https://openalex.org/W2131431703","https://openalex.org/W2134852441","https://openalex.org/W2138296752","https://openalex.org/W2140471892","https://openalex.org/W2145248244","https://openalex.org/W2147155432","https://openalex.org/W2148715572","https://openalex.org/W2150654293","https://openalex.org/W2151701113","https://openalex.org/W2154972651","https://openalex.org/W2159742257","https://openalex.org/W2163839019","https://openalex.org/W2167516391","https://openalex.org/W4243964560"],"related_works":["https://openalex.org/W2100159933","https://openalex.org/W7026704265","https://openalex.org/W2168217593","https://openalex.org/W2028715664","https://openalex.org/W2113587271","https://openalex.org/W2047386459","https://openalex.org/W2041542428","https://openalex.org/W2060677877","https://openalex.org/W2147912438","https://openalex.org/W1553897292"],"abstract_inverted_index":{"AIM:":[0],"11":[1],"beta-hydroxysteroid":[2],"dehydrogenase":[3],"type":[4],"1":[5],"(11beta-HSD1)":[6],"is":[7],"considered":[8],"to":[9,11,23,67,123,222,238],"contribute":[10],"the":[12,15,34,39,46,50,55,71,125,208,258,268,277],"aetiology":[13],"of":[14,33,41,52,57,73,111,127,133,249,260,271],"metabolic":[16,263,278],"syndrome,":[17,35],"and":[18,30,43,49,98,116,119,151,170,216,242],"specific":[19,75],"inhibitors":[20,273],"have":[21],"begun":[22],"emerge":[24],"as":[25],"treatments":[26],"for":[27,148],"insulin":[28,113],"resistance":[29],"other":[31],"facets":[32],"including":[36],"atherosclerosis.":[37,63,117,283],"Given":[38],"role":[40],"glucocorticoids":[42],"11beta-HSD1":[44,59,76,141,235,272],"in":[45,54,69,103,130,139,143,154,178,192,199,207,220,228,246,257,274],"anti-inflammatory":[47],"response":[48,221],"involvement":[51],"inflammation":[53],"development":[56],"atherosclerosis,":[58],"inhibition":[60,236],"may":[61],"exacerbate":[62],"Our":[64],"aim":[65],"was":[66,137,152,231],"investigate":[68],"vivo":[70],"effects":[72],"a":[74,88,108,225,247],"inhibitor":[77],"(2922)":[78],"on":[79],"atherosclerosis":[80,217],"while":[81],"assessing":[82],"glucose":[83,156,168,240],"homeostasis.":[84],"METHODS:":[85],"We":[86],"conducted":[87],"12-week":[89],"study":[90,266],"administering":[91],"2922":[92,136,182],"(at":[93],"three":[94],"doses,":[95],"3,":[96],"10":[97],"100":[99,149],"mg/kg":[100],"body":[101,200],"weight)":[102],"Ldlr":[104],"3KO":[105],"(Ldlr(-/-)Apob(100/100)Lep(ob/ob))":[106],"mice,":[107],"genetic":[109],"model":[110,129,172],"obesity,":[112],"resistance,":[114],"dyslipidaemia":[115],"Rosiglitazone":[118],"simvastatin":[120],"were":[121,175,197,218],"used":[122],"test":[124],"responsiveness":[126],"our":[128],"both":[131],"types":[132],"therapy.":[134],"RESULTS:":[135],"effective":[138],"reducing":[140],"activity":[142],"inguinal":[144],"adipose":[145,202],"tissue":[146,205],"(>90%":[147],"mg/kg)":[150,184],"efficacious":[153],"improving":[155],"homeostasis":[157],"at":[158],"doses":[159],">":[160],"or":[161,203],"=10":[162],"mg/kg.":[163],"Plasma":[164],"insulin,":[165],"blood":[166],"glucose,":[167],"tolerance":[169],"homeostatic":[171],"assessment":[173],"indices":[174],"all":[176],"improved":[177,239],"mice":[179],"treated":[180],"with":[181,186,276],"(100":[183],"compared":[185],"control":[187],"animals.":[188],"Despite":[189],"an":[190],"improvement":[191],"these":[193],"parameters,":[194],"no":[195],"differences":[196],"observed":[198],"weight,":[201],"lean":[204],"masses":[206],"2922-treated":[209],"mice.":[210],"Interestingly,":[211],"circulating":[212],"lipids,":[213],"proinflammatory":[214],"cytokines":[215],"unaltered":[219],"2922,":[223],"although":[224],"small":[226],"reduction":[227],"LDL":[229],"cholesterol":[230],"detected.":[232],"CONCLUSIONS:":[233],"Importantly,":[234],"leads":[237],"metabolism":[241],"does":[243],"not":[244],"result":[245],"worsening":[248],"atherosclerotic":[250],"lesion":[251],"area,":[252],"yet":[253],"retained":[254],"antidiabetic":[255],"potential":[256,269],"face":[259],"multiple":[261],"severe":[262],"aberrations.":[264],"This":[265],"reinforces":[267],"use":[270],"patients":[275],"syndrome":[279],"without":[280],"negatively":[281],"impacting":[282]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1968156583","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
